378 related articles for article (PubMed ID: 1532675)
1. Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates.
Innis RB; Malison RT; al-Tikriti M; Hoffer PB; Sybirska EH; Seibyl JP; Zoghbi SS; Baldwin RM; Laruelle M; Smith EO
Synapse; 1992 Mar; 10(3):177-84. PubMed ID: 1532675
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of 5-[18F]fluoropropylepidepride as a potential PET radioligand for imaging dopamine D2 receptors.
Kessler RM; Votaw JR; de Paulis T; Bingham DR; Ansari MS; Mason NS; Holburn G; Schmidt DE; Votaw DB; Manning RG
Synapse; 1993 Nov; 15(3):169-76. PubMed ID: 8278895
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo D2-dopamine receptor binding with [123I]S(-) iodobenzamide ([123I]IBZM) in rat and human brain.
Verhoeff NP; Bobeldijk M; Feenstra MG; Boer GJ; Maas MA; Erdtsieck-Ernste E; de Bruin K; van Royen EA
Int J Rad Appl Instrum B; 1991; 18(8):837-46. PubMed ID: 1839302
[TBL] [Abstract][Full Text] [Related]
4. SPECT imaging of striatal dopamine release after amphetamine challenge.
Laruelle M; Abi-Dargham A; van Dyck CH; Rosenblatt W; Zea-Ponce Y; Zoghbi SS; Baldwin RM; Charney DS; Hoffer PB; Kung HF
J Nucl Med; 1995 Jul; 36(7):1182-90. PubMed ID: 7790942
[TBL] [Abstract][Full Text] [Related]
5. Effect of the haloperidol tetrahydropyridine metabolite 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6- tetrahydropyridine on dopamine receptor and transporter binding. A nonhuman primate 123I-iodobenzamide and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane single photon emission computed tomographic study.
Oliver DW; Dormehl IC; Van der Schyf CJ; Neumeyer JL; Hugo N; Keeve R; Rossouw NT; Müller-Gärtner HW; Castagnoli N
Arzneimittelforschung; 1997 Jun; 47(6):692-9. PubMed ID: 9239444
[TBL] [Abstract][Full Text] [Related]
6. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
Seibyl JP; Zea-Ponce Y; Brenner L; Baldwin RM; Krystal JH; Offord SJ; Mochoviak S; Charney DS; Hoffer PB; Innis RB
J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
[TBL] [Abstract][Full Text] [Related]
7. High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain.
Kessler RM; Votaw JR; Schmidt DE; Ansari MS; Holdeman KP; de Paulis T; Clanton JA; Pfeffer R; Manning RG; Ebert MH
Life Sci; 1993; 53(3):241-50. PubMed ID: 8321085
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of d-amphetamine effects on the binding of dopamine D-2 receptor radioligand, 18F-fallypride in nonhuman primates using positron emission tomography.
Mukherjee J; Yang ZY; Lew R; Brown T; Kronmal S; Cooper MD; Seiden LS
Synapse; 1997 Sep; 27(1):1-13. PubMed ID: 9268060
[TBL] [Abstract][Full Text] [Related]
9. Dynamic SPECT imaging of dopamine D2 receptors in human subjects with iodine-123-IBZM.
Seibyl JP; Woods SW; Zoghbi SS; Baldwin RM; Dey HM; Goddard AW; Zea-Ponce Y; Zubal G; Germine M; Smith EO
J Nucl Med; 1992 Nov; 33(11):1964-71. PubMed ID: 1432157
[TBL] [Abstract][Full Text] [Related]
10. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates.
Laruelle M; Iyer RN; al-Tikriti MS; Zea-Ponce Y; Malison R; Zoghbi SS; Baldwin RM; Kung HF; Charney DS; Hoffer PB; Innis RB; Bradberry CW
Synapse; 1997 Jan; 25(1):1-14. PubMed ID: 8987142
[TBL] [Abstract][Full Text] [Related]
11. Behavioral changes and [123I]IBZM equilibrium SPECT measurement of amphetamine-induced dopamine release in rhesus monkeys exposed to subchronic amphetamine.
Castner SA; al-Tikriti MS; Baldwin RM; Seibyl JP; Innis RB; Goldman-Rakic PS
Neuropsychopharmacology; 2000 Jan; 22(1):4-13. PubMed ID: 10633485
[TBL] [Abstract][Full Text] [Related]
12. High affinity dopamine D2 receptor radioligands. 2. [125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors.
Kessler RM; Ansari MS; Schmidt DE; de Paulis T; Clanton JA; Innis R; al-Tikriti M; Manning RG; Gillespie D
Life Sci; 1991; 49(8):617-28. PubMed ID: 1830917
[TBL] [Abstract][Full Text] [Related]
13. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
[TBL] [Abstract][Full Text] [Related]
14. Blockade of in vivo binding of 125I-labeled 3-iodobenzamide (IBZM) to dopamine receptors by D2 antagonist and agonist.
Singhaniyom W; Tsai YF; Brücke T; McLellan CA; Cohen RM; Kung HF; Chiueh CC
Brain Res; 1988 Jun; 453(1-2):393-6. PubMed ID: 2969766
[TBL] [Abstract][Full Text] [Related]
15. Comparison of three high affinity SPECT radiotracers for the dopamine D2 receptor.
al-Tikriti MS; Baldwin RM; Zea-Ponce Y; Sybirska E; Zoghbi SS; Laruelle M; Malison RT; Kung HF; Kessler RM; Charney DS
Nucl Med Biol; 1994 Feb; 21(2):179-88. PubMed ID: 9234281
[TBL] [Abstract][Full Text] [Related]
16. A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls.
Tibbo P; Silverstone PH; McEwan AJ; Scott J; Joshua A; Golberg K
J Psychiatry Neurosci; 1997 Jan; 22(1):39-45. PubMed ID: 9002391
[TBL] [Abstract][Full Text] [Related]
17. Dopamine D2 receptor binding is reduced in Wilson's disease: correlation of neurological deficits with striatal 123I-iodobenzamide binding.
Oder W; Brücke T; Kollegger H; Spatt J; Asenbaum S; Deecke L
J Neural Transm (Vienna); 1996; 103(8-9):1093-103. PubMed ID: 9013397
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with the tetrahydropyridine analog (HPTP) of haloperidol influences dopamine ligand binding in baboon brain. An [123I]iodobenzamide (IBZM) SPECT study.
Van der Schyf CJ; Dormehl IC; Oliver DW; Hugo N; Keeve R; Müller-Gärtner HW; Pond SM; Castagnoli N
Brain Res Mol Brain Res; 1996 Dec; 43(1-2):251-8. PubMed ID: 9037540
[TBL] [Abstract][Full Text] [Related]
19. No direct correlation between behaviorally active doses of the dopamine D2 agonist LY 171555 and displacement of [123I]IBZM as measured with SPECT in MPTP monkeys.
Vermeulen RJ; Drukarch B; Verhoeff NP; Goosen C; Sahadat MC; Wolters EC; van Royen EA; Stoof JC
Synapse; 1994 Jun; 17(2):115-24. PubMed ID: 7916490
[TBL] [Abstract][Full Text] [Related]
20. Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging.
Leslie WD; Abrams DN; Greenberg CR; Hobson D
J Nucl Med; 1996 Oct; 37(10):1589-91. PubMed ID: 8862288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
